Add-back not checked

ObsEva SA

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily”In the company’s words, NCT03070951 on ClinicalTrials.gov
Tested for
Uterine Fibroids (2 trials), Heavy Menstrual Bleeding (2 trials)
Main trialPhase 3
“The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.”In the company’s words, NCT03070951 on ClinicalTrials.gov

Other drugs for Uterine Fibroids

All 3 drugs for Uterine Fibroids

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Completed 16 Sep 2019 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3Completed 14 Apr 2020 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Add-back

Following is part of Solo: you see every change to Add-back the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in